Compare AbCellera Biologics Inc (ABCL) vs iShares MSCI Indonesia ETF (EIDO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs iShares MSCI Indonesia ETF — how do they compare? AbCellera Biologics Inc trades at $7.18 (market cap $2.35B), while iShares MSCI Indonesia ETF trades at $11.71. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, iShares MSCI Indonesia ETF nearer its low. Which is the better fit depends on your goals.
| ABCL | EIDO | |
|---|---|---|
Market Cap | $2.35B | — |
Sector | Health | — |
52-Week High | $8.12 | $19.22 |
52-Week Low | $2.78 | $10.80 |
Enterprise Value | $1.99B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
EIDO (iShares MSCI Indonesia ETF) trades at $11.81, up 3.14% today, but technical indicators show a bearish trend with selling pressure outweighing buying signals. The ETF faces headwinds from Indonesia's monetary policy tightening and dividend reductions, with key financial ratios currently unavailable for fundamental assessment. Recent news highlights Indonesia's economic initiatives including AI integration in government programs and reforestation efforts.
The outlook remains cautious as Bank Indonesia's rate hikes to defend the rupiah create currency volatility risks. While long-term GDP growth potential exists through government initiatives, near-term pressures from dividend cuts and technical bearishness suggest careful monitoring of Indonesian economic stability and ETF performance metrics is warranted for investors seeking emerging market exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →
